Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Galapagos NV

Market Cap 1.64B 1.9B 1.9B 1.51B 1.42B 2.66B 181B 2.7B 17.88B 6.97B 88.03B 7.14B 6.99B 305B P/E Ratio 2026 *
-10.8x
P/E Ratio 2027 * -9.97x
Enterprise Value -1.16B -1.34B -1.34B -1.07B -1B -1.87B -128B -1.9B -12.61B -4.92B -62.1B -5.04B -4.93B -215B EV / Sales 2026 *
-6.4x
EV / Sales 2027 * -4.93x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-12
Director of Finance/CFO 43 2025-07-06
Chief Tech/Sci/R&D Officer 61 2026-06-07
Director TitleAgeSince
Director/Board Member 64 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-12
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%-0.22%-15.03%-12.88% 42.96B
+3.11%+3.11%+274.29%+507.94% 31.73B
+0.22%-1.08%+14.03%-14.37% 30.22B
+1.62%-2.08%-4.36%+24.05% 28.94B
+4.09%-1.98%+11.99%+17.37% 23.87B
-1.63%+2.88%+53.73%+114.36% 13.57B
-0.40%-1.48%+7.48%+7.12% 12.96B
+1.14%+3.62% - - 13.39B
-0.74%-1.62%+105.71%+76.01% 12.2B
Average +0.63%-0.71%+55.98%+89.95% 23.31B
Weighted average by Cap. +0.80%-1.08%+54.76%+95.75%

Financials

2026 *2027 *
Net sales 181M 210M 210M 167M 156M 293M 19.93B 297M 1.97B 768M 9.7B 787M 770M 33.59B 177M 205M 205M 163M 153M 287M 19.52B 291M 1.93B 753M 9.5B 771M 754M 32.9B
Net income -236M -273M -273M -217M -203M -381M -25.94B -387M -2.56B -1B -12.63B -1.02B -1B -43.72B -144M -167M -167M -133M -124M -233M -15.88B -237M -1.57B -612M -7.73B -627M -614M -26.76B
Net Debt -2.8B -3.25B -3.25B -2.58B -2.42B -4.53B -308B -4.6B -30.5B -11.89B -150B -12.18B -11.92B -520B -2.52B -2.92B -2.92B -2.32B -2.17B -4.07B -277B -4.13B -27.4B -10.68B -135B -10.94B -10.71B -467B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
B
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!